iBio, Inc. is a biotech company providing development and manufacturing services for third-party customers in the US. The company's key focus is on its lead therapeutic candidate IBIO-100, which is being developed as a potential treatment for systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio, Inc. is involved in the development of vaccine candidates, recombinant proteins, and provides a range of process development, manufacturing, and bio-analytics services.